IRODALOM:
1. Hansen JM, Wildner-Christensen M, Schaffalitzky de Muckadell OB.: Gastroesophageal reflux symptoms in a Danish population: a prospective follow-up analysis of symptoms, quality of life, and health-care use. Am J Gastroenterol. 2009 Oct;104(10):2394-403.
2. Edelstein ZR, Bronner MP, Rosen SN, Vaughan TL.: Risk factors for Barrett’s esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol. 2009 Apr;104(4):834-42.
3. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P.: Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994- 2006 Gut 2009;58:182-188.
4. El-Serag HB, Fairly K, Shub MD, Integlia M, Gilger MA; Henderson L.: Barrett’s Esophagus in Children and Adolescents Without Neurodevelopmental or Tracheoesophageal Abnormalities Gastrointestinal Endoscopy 2009, 69 (5): AB100.
5. Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, Buffler P, Corley DA.: Alcohol types and sociodemo- graphic characteristics as risk factors for Barrett’s esophagus. Gastroenterology. 2009 Mar; 136(3):806-15.
62 Gastro Update 2010
6. Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, McGuigan J, Comber H, Reynolds JV, Murray LJ.: The association between alcohol and reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Gastroenterology. 2009 Mar;136(3):799-805.
7. El-Serag HB, Lagergren J.: Alcohol drinking and the risk of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2009 Apr;136(4):1155-7.
8. Mulholland HG, Cantwell MM, Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, McGuigan J, Reynolds JV, Comber H, Murray LJ.: Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Cancer Causes Control. 2009 Apr;20(3):279-88.
9. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE.: Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females Gut 2009;58:16-23.
10. Chak A, Falk G, Grady WM, Kinnard M, Elston R, Mittal S, King JF, Willis JE, Kondru A, Brock W, Barnholtz-Sloan J.: Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. Am J Gastroenterol. 2009 Aug;104(8):1913-21.
11. Wang VS, Hornick JL, Sepulveda JA, Mauer R, Poneros JM.: Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett’s esophagus: a 20-year experience. Gastrointest Endosc. 2009 Apr;69(4):777-83.
12. Ngamruengphong S, Sharma VK, Das A.: Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc. 2009 May;69(6):1021-8.
13. Curvers WL, van den Broek FJ, Reitsma JB, Dekker E, Bergman JJ.: Systematic review of narrow-band imaging for the detection and differentiation of abnormalities in the esophagus and stomach (with video). Gastrointest Endosc. 2009 Feb;69(2):307-17.
14. Curvers WL, Singh R, Wallace MB, Song LM, Ragunath K, Wolfsen HC, ten Kate FJ, Fockens P, Bergman JJ.:
Identification of predictive factors for early neoplasia in Barrett’s esophagus after autofluorescence imaging: a stepwise multicenter structured assessment. Gastrointest Endosc. 2009 Jul;70(1):9-17.
15. Thomas T, Singh R, Ragunath K: Trimodal imaging-assisted endoscopic mucosal resection of early Barrett’s neoplasia.. Surg Endosc. 2009 Jul;23(7):1609-13.
16. Osawa H, Yamamoto H, Yamada N, Yoshizawa M, Sunada K, Kita H, Ajibe H, Satoh K, Sugano K.:
Diagnosis of endoscopic Barrett’s esophagus by transnasal flexible spectral imaging color enhancement. J Gastroenterol. 2009;44(11):1125-32.
17. Dunbar KB, Okolo P 3rd, Montgomery E, Canto MI.: Confocal laser endomicroscopy in Barrett’s esophagus and endoscopically inapparent Barrett’s neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc. 2009 Oct;70(4):645-54.
18. Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A.: A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease.. Am J Gastroenterol. 2009 Jun;104(6):1533-9.
19. Liao Z, Gao R, Xu C, Xu DF, Li ZS.: Sleeve string capsule endoscopy for real-time viewing of the esophagus: a pilot study (with video). Gastrointest Endosc. 2009 Aug;70(2):201-9.
20. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, Olaru AV, Paun BC, Yang J, Kan T, Ito T, Hamilton JP, Selaru FM, Agarwal R, David S, Abraham JM, Wolfsen HC, Wallace MB, Shaheen NJ, Washington K, Wang J, Canto MI, Bhattacharyya A, Nelson MA, Wagner PD, Romero Y, Wang KK, Feng Z, Sampliner RE, Meltzer SJ.: A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009 May 15;69(10):4112-5.
A nyelõcsõ 63
21. Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, Wang S, Herman JG, Canto MI.:
DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus. Am J Gastroenterol. 2009 Sep;104(9):2153-60.
22. Binato M, Gurski RR, Fagundes RB, Meurer L, Edelweiss MI.: P53 and Ki-67 overexpression in gastroesophageal reflux disease–Barrett’s esophagus and adenocarcinoma sequence. Dis Esophagus. 2009;22(7):588-95.
23. Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.: Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroenterol. 2009 Nov;104(11):2673-80.
24. Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS, Bernstein H.: Expression of bile acid transporting proteins in Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2009 Feb;104(2):302-9.
25. Lao-Sirieix P, Boussioutas A, Kadri SR, O’Donovan M, Debiram I, Das M, Harihar L, Fitzgerald RC.:
Non-endoscopic screening biomarkers for Barrett’s oesophagus: from microarray analysis to the clinic. Gut. 2009 Nov;58(11):1451-9.
26. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ.: A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009 Jun; 136(7):2101-2114.
27. Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK.: An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009 May;41(5):400-8.
28. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ.: Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009 May 28;360(22):2277-88.
29. Sharma VK, Jae Kim H, Das A, Wells CD, Nguyen CC, Fleischer DE.: Circumferential and focal ablation of Barrett’s esophagus containing dysplasia. Am J Gastroenterol. 2009 Feb;104(2):310-7.
30. Pouw RE, Gondrie JJ, Rygiel AM, Sondermeijer CM, ten Kate FJ, Odze RD, Vieth M, Krishnadath KK, Bergman JJ.: Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am J Gastroenterol. 2009 Jun;104(6):1366-73.
31. Chennat J, Konda VJ, Ross AS, de Tejada AH, Noffsinger A, Hart J, Lin S, Ferguson MK, Posner MC, Waxman I.: Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma – an American single-center experience. Am J Gastroenterol. 2009 Nov;104(11):2684-92.
32. Chennat J, Ross AS, Konda VJ, Lin S, Noffsinger A, Hart J, Waxman I.: Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management. Gastrointest Endosc. 2009 Sep;70(3):417-21.
33. Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, Dunagan KT, Lutzke LS, Borkenhagen LS, Wang KK.: Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009 Sep;137(3):815-23.
34. Yachimski P, Puricelli WP, Nishioka NS.: Patient predictors of histopathologic response after photodynamic therapy of Barrett’s esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc. 2009 Feb;69(2):205-12.
35. Bajbouj M, Becker V, Eckel F, Miehlke S, Pech O, Prinz C, Schmid RM, Meining A.: Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations.
64 Gastro Update 2010
Gastroenterology. 2009 Aug;137(2):440-4.
36. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ.: Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009 Nov;137(5):1776-84.
37. de Vries DR, Ter Linde JJ, van Herwaarden MA, Schwartz MP, Shephard P, Geng MM, Smout AJ, Samsom M.: In GERD patients, mucosal repair associated genes are upregulated in non-inflamed oesophageal epithelium. J Cell Mol Med. 2009 May;13(5):936-47.
38. de Vries DR, ter Linde JJ, van Herwaarden MA, Smout AJ, Samsom M: Gastroesophageal reflux disease is associated with the C825T polymorphism in the G-protein beta3 subunit gene (GNB3). de Vries DR, ter Linde JJ, van Herwaarden MA, Smout AJ, Samsom M. Am J Gastroenterol. 2009 Feb; 104(2):281-5.
39. Asling B, Jirholt J, Hammond P, Knutsson M, Walentinsson A, Davidson G, Agreus L, Lehmann A, Lagerström-Fermer M.: Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia. Gut. 2009 Aug;58(8):1063-9.
40.* Agrawal A, Roberts J, Sharma N, Tutuian R, Vela M, Castell DO.: Symptoms with acid and nonacid reflux may be produced by different mechanisms. Dis Esophagus. 2009;22(5):467-70.
41. Ang D, Blondeau K, Sifrim D, Tack J.: The spectrum of motor function abnormalities in gastroesophageal reflux disease and Barrett’s esophagus. Digestion. 2009;79(3):158-68.
42. Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, Tack J, Heading RC, Holtman G, Moss SF: The Vevey NERD Consensus Group. Vevey NERD Consensus Group: Diagnosis and management of non-erosive reflux diseaseDigestion. 2009;80(2):74-88.
43. Bansal A, Wani S, Rastogi A, Rastogi K, Goyal A, Hall S, Singh V, Higbee A, Sharma P.: Impact of measurement of esophageal acid exposure close to the gastroesophageal junction on diagnostic accuracy and event-symptom correlation: a prospective study using wireless dual pH monitoring. Am J Gastroenterol. 2009 Dec;104(12):2918-25.
44. Manabe T. et al.: Observation of gastro-esophageal reflux by MRI: a feasisility study. Abdom Imaging 2009;34:419-423
45. Kinoshita Y, Ashida K, Miwa H, Hongo M.: The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor. Am J Gastroenterol. 2009 May;104(5):1106-11.
46. Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA.: American Lung Association Asthma Clinical Research Centers, Efficacy of esomeprazole for treatment of poorly controlled asthma.. N Engl J Med. 2009 Apr 9;360(15):1487-99.
47. Kiljander TO, Junghard O, Beckman O, Lind T.: Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma: A Randomized, Placebo-controlled Study. Am J Respir Crit Care Med. 2010 Jan 28. [Epub ahead of print].
48. Gill SK, O’Brien L, Einarson TR, Koren G.: The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009 Jun;104(6):1541-5.
49. Gill SK, O’Brien L, Koren G.: The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig Dis Sci. 2009 Sep;54(9):1835-8.
50. Lehmann A, Antonsson M, Holmberg AA, Blackshaw LA, Brändén L, Bräuner-Osborne H, Christiansen B, Dent J, Elebring T, Jacobson BM, Jensen J, Mattsson JP, Nilsson K, Oja SS, Page AJ, Saransaari P, von Unge S.: (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABA-B receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action J Pharmacol Exp Ther. 2009 Nov;331(2):504-12.
A nyelõcsõ 65
51. Keywood C, Wakefield M, Tack J.: A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut. 2009 Sep;58(9):1192-9.
52. Ganz RA, Fallon E, Wittchow T, Klein D.: A new injectable agent for the treatment of GERD: results of the Durasphere pilot trial. Gastrointest Endosc. 2009 Feb;69(2):318-23.
53. Soricelli E.,Basso N., Genco A., Cipriano M.: Long-term results of hiatal hernia mesh repair and antireflux laparoscopic surgery. Surg Endosc 2009, April (Epub).
54.* Horváth Örs P.: Surgical treatment for early Barrett cancer. Magy Seb 2009;62:51-58.
55.* Hölscher A.H., Vallböhmer D., Gutschow C., Bollschweiler E.: Reflux esophagitis, high-grade neoplasia, and early Barrett’s carcinoma -what is the place of the Merendino procedure? Langenbecks Arch Surg 2009;394:417-24.
56. Csendes A., Braghetto I., Burdiles P., Smok G.,Henríquez A., Burgos A.M.: Late Results of the Surgical Treatment of 125 Patients With Short-Segment Barrett Esophagus. Arch Surg 2009;144(10):921-27.
57. DeMeester S.R.: Questions Regarding Surgery to Correct Short-Segment BE Comment on “Late Results of the Surgical Treatment of 125 Patiens With Short-Segment Barrett Esophagus”. Arch Surg. 2009; 144(10):927.
58. Ceccarelli G., Patriti A., Biancafarina A., Spaziani A., Bartoli A., Bellochi R., Casciola L.: Intraoperative and Postoperative Outcome of Robot-Assisted and Traditional Laparoscopic Nissen Fundoplication. Eur Surg Res 2009;43:198-03.
59.* Müller-Stich B.P., Köninger J., Müller-Stich B.H., Schafer F., Warschkow R., Mehrabi A., Gutt C.N.:
Laparoscopic mesh-augmented hiatoplasty as a method to treat gastroesophageal reflux without fundoplication: single-center experience with 306 consecutive patients. Am J Surg 2009;198:17-24.
60. Agrawal S., Shapey I., Peacock A., Ali A., Super P.: Prospective Study of Routine Day-Case Laparoscopic Modified Lind Partial Fundoplication. World J Surg. 2009;33:1229-34.
61. Demyttenaere S.V., Bergman S., Pham T., Anderson J., Dettorre R., Melvin W.S., Mikami D.J.: Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 2009, September (Epub).
62. Cadiére G.B., Van Sante N., Graves J.F., Gawlicka A.K., Rajan A.: Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc 2009;23(5):957-64.
63.* Ruiz-Tovar J., Tabernilla M.D., Chames A., Morales V., Martinez-Molina E.: Clinical Outcome at 10 Years After Laparoscopic Versus Open Nissen Fundoplication. J Lap Adv Surg Tech 2009, November (Epub).
64. Thompson S.K., Cai W., Jamieson G.G., Zhang A.Y., Myers J.C., Parr Z.E., Watson D.I., Persson J., Holtmann G., Devitt P.G.: Recurrent Symtomps after Fundoplication with a Negative pH Study – Recurrent Reflux or Functional Heartburn? J Gastr Surg 2009;13:54-60.
65. Mitchell E.M., Pal N., Kalyan J.P., Rhodes M., Lewis M.P.N.: Poor outcome of oesophageal adenocarcinoma after prior antireflux surgery. Int J Surg 2009;7:566-69.
66. Lord R.V.N., DeMeester S.R., Peters J.H., Hagen J.A., Elyssina D., Sheth C.T., DeMeester T.R.: Hiatal Hernia, Lower Esophageal Sphincter Incompetence, and Effectiveness of Nissen Fundoplication int he Spectrum of Gastroesophageal Reflux Dis J Gastr Surg 2009;13:602-10.
67. Lamb P.J., Myers J.C., Jamieson G.G., Thompson S.K., Devitt P.G., Watson D.I.: Long-term outcomes of revisional surgery following laparoscopic fundoplication. Br J Surg 2009;96:391-97.
68. Miyoshi K. et al: Abnormal fluorine-18-fluorodeoxyglucose uptake in benign esophageal le iomyoma. Gen Thorac Cardiovasc Surg 2009;57:629-632.
69. Asteriou C., Konstantinou D., Lalountas M:, Kleontas A., Setzis K., Zafiriou G., Barbetakis N.: Nine
66 Gastro Update 2010
years in surgical approach of leiomyomatosis of esophagus. World J Surg Onc 2009;7:102-05.
70. Obuchi T., Sasaki A., Nitta H., Koeda K., Ikeda K., Wakabayashi G.: Minimally invasive surgical enucleation for esophageal leiomyoma: report of seven cases. Dis Esoph 2009, January (Epub).
71. Ulla M. et al: Esophageal cancer: pneumo-64-MDCT. Abdom Imaging (Published online: 30 June 2009).
72. Carrascosa P. et al: Esophageal stenosis: three-dimensional multidetector CT and virtual endoscopy.
Abdom Imaging 2009;34:19-25.
73. Jin G.Y. et al: Usefulness of MDCT evaluation of the intraluminal surface of esophageal masses using only effervescent powder without injection of hypotonic agent. Abdom Imaging 2009;34:424-429.
74. Ba-Ssalamah A. et al: Dedicated multi-detector CT of the esophagus: spectrum of diseases. Abdom Imaging 2009;34:3-18.
75. Chen T-W. et al: Quantitative assessment of first-pass perfusion of oesophagealnsquamous cell carcinoma using 64-section MDCT: initial observation. Clinical Radiology 2009; 64:38-45.
76. Sakurada A. et al: Diagnostic performance of diffusion-wighted magnetic resonance imaging in esophageal cancer. Eur Radiol 2009;19:1461-1469.
77. Krause B.J. et al: 18F-FDG PET and 18F-FDG PET/CT for assessing Response to therapy in esophageal cancer. J Nucl Med 2009;50:89S-96S.
78. Noble F. et al: Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clinical Radiology 2009;64:699-705.
79. Kim T.J. et al: Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009;29:403-21.
80. Lee K.E. et al: Management of airway involvement of oesophageal cancer using covered retrivable nitinol stents. Clinical Radiology 2009;64:133-141.
81. Badreddine RJ, Prasad GA, Lewis JT, Lutzke LS, Borkenhagen LS, Dunagan KT, Wang KK.: Depth of Submucosal Invasion Does Not Predict Lymph Node Metastasis and Survival of Patients with Esophageal Carcinoma. Clin Gastroenterol Hepatol. 2009 Nov 27. [Epub ahead of print].
82.* Faller J.: The change in surgical treatment of the oesophageal cancer during the past 50 years. Magy Seb 2009;62(1):4-8.
83.* Mariette C.: Current standards and options in the treatment of squamous cell oesophageal carcinoma. Eur J Cancer 2009;45:452-54.
84.* Aly A., Jamieson G.G., Watson D.I., Devitt P.G., Ackroyd R., Stoddard C.J.: An Antireflux Anastomosis Following Esophagectomy: A Randomized Controlled Trial. J Gastrointest Surg 2009, December (Epub)
85. D’Journo X.,B., Martin J., Rakovich G., Brigand C., Gaboury L., Ferraro P., Duranceau A.: Mucosal Damage in the Esophageal Remnant After Esophagectomy and Gastric Transposition. Ann Surg 2009; 249:262-68.
86. Blomberg J., Wenger U., Lagergen J., Arnelo U., Agustsson T., Johnsson E., Toth E., Lagergen P.:
Antireflux stent versus conventional stent in the palliation of distal esophageal cancer. A randomized, multicenter clinical trial. Scand J Gast 2009. December (Epub).
87. Ly J, Cao XF, Zhu B, Ji L, Tao L, Wang DD.: Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol. 2009 Oct 21;15(39):4962-8.
88. Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH.: Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol. 2009 Dec 21;15(47):5983-91.
89. Wijnhoven BP, van Lanschot JJ, Tilanus HW, Steyerberg EW, van der Gaast A.: Neoadjuvant
A nyelõcsõ 67
Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses. World J Surg. 2009 Sep 16. [Epub ahead of print].
90. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, Nakatani K, Ishido K, Naruke A, Ryu T.:
Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res. 2009 Jul;3(4):153-61.
91. Morgan MA, Lewis WG, Casbard A, Roberts SA, Adams R, Clark GW, Havard TJ, Crosby TD.:
Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. Br J Surg. 2009 Nov;96(11):1300-7.
92. Ajani J.: A (J Clin Oncol. 2009, Jan. 20:27 (3) 467-8.
93. Ebert MP, Auernhammer C, Caca K, Eckel F, Fischbach W, Geissler M, Göke B, Greten T, Kubicka S, Lutz MP, Möhler M, Opitz O, Pavel M, Porschen R, Reinacher-Schick A, Schmiegel W, Seufferlein T, Wiedenmann B, Schmid RM.: [Gastrointestinal oncology – therapy update 2008 / 2009] Z Gastroenterol. 2009 Mar;47(3):296-306. Epub 2009 Mar 6.
94. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F.: Gastroenterol Clin Biol. 2009 Jun-Jul;33(6-7):491-2. Br J Cancer. 2008 Oct 7;99(7):1020-6. Epub 2008 Sep 16.
95. Jiang Y, Kimchi E, Ajani JA.: Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol. 2009 Mar;5(2):157-61.
96. Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M.: Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer. 2009 Nov 22;9:408.
97. Homs MY, Voest EE, Siersema PD.: Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs. 2009 Jun;14(2):329-39.
98. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M.:
p53 Mutation Status Predicts Pathological Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer. Ann Surg Oncol. 2009 Nov 3. [Epub ahead of print].
99. Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, Yasuda T, Matsuyama J, Mori M, Doki Y.: p53 Genotype Predicts Response to Chemotherapy in Patients with Squamous Cell Carcinoma of the Esophagus. Ann Surg Oncol. 2009 Nov 26. [Epub ahead of print].
100. Akita H, Doki Y, Yano M, Miyata H, Miyashiro I, Ohigashi H, Ishikawa O, Nishiyama A, Imaoka S.:
Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus. 2009;22(4):291-7. Epub 2008 Nov 19.
101. Lee PC, Port JL, Paul S, Stiles BM, Altorki NK.: Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Surg. 2009 Jul;88(1):186-92; discussion 192-3.
102. Miyoshi N, Yano M, Takachi K, Kishi K, Noura S, Eguchi H, Yamada T, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Doki Y, Imaoka S.: Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol. 2009 Apr 1; 99(5): 302-6.
103. Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A, Nishiyama K.: Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):123-9.
104. Bollschweiler E, Hölscher AH, Metzger R.: Histologic tumor type and the rate of complete response
68 Gastro Update 2010
after neoadjuvant therapy for esophageal cancer. Future Oncol. 2010 Jan;6(1):25-35.
105. Saif MW, Choma A, Salamone SJ, Chu E.: Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009 Nov 18;101(22):1543-52. Epub 2009 Oct 19.
106. Boone J, Livestro DP, Elias SG, Borel Rinkes IH, van Hillegersberg R.: International survey on esophageal cancer: part II staging and neoadjuvant therapy. Dis Esophagus. 2009;22(3):203-10. Epub 2009 Jan 23.
107. Boone J, Livestro DP, Elias SG, Borel Rinkes IH, van Hillegersberg R.: International survey on esophageal cancer: part I surgical techniques. Dis Esophagus. 2009;22(3):195-202. Epub 2009 Jan 23.
108. Elstad NL, Fowers KD.: OncoGel (ReGel/paclitaxel)–clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev. 2009 Aug 10;61(10):785-94. Epub 2009 May 5.
109. DuVall GA, Tarabar D, Seidel RH, Elstad NL, Fowers KD.: Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anticancer Drugs. 2009 Feb; 20(2):89-95.
110. Chen Tian-wu et al: Evaluation of entire gastric fundic and esophageal varices secondary to posthepatitc cirrhosis: portal venography using 64-row MDCT. Abdom Imaging (Published online: 27 February 2009).
111. Goshima S. et al: Detection and grading for esophageal varices in patients with chronic liver damage: comparison of gadolinium enhanced and unenhanced steady-state coherent MR images. Magnetic Resonance Imaging 27 2009;27:1230-1235.
112. Lu Y, Gao R, Liao Z, Hu LH, Li ZS.: Meta-analysis of capsule endoscopy in patients diagnosed or suspected with esophageal varices. World J Gastroenterol. 2009 Mar 14;15(10):1254-8.
113. Kong DR, Xu JM, Zhang L, Zhang C, Fu ZQ, He BB, Sun B, Xie Y.: Computerized endoscopic balloon manometry to detect esophageal variceal pressure.. Endoscopy. 2009 May;41(5):415-20.
114. Vegesna AK, Chung CY, Bajaj A, Tiwana MI, Rishikesh R, Hamid I, Kalra A, Korimilli A, Patel S, Mamoon R, Riaz J, Miller LS.: Minimally invasive measurement of esophageal variceal pressure and wall tension (with video). Gastrointest Endosc. 2009 Sep;70(3):407-13.
115.* Orloff M.J., Isenberg J.I., Wheeler H.O., Haynes K.S., Jinich-Brook H., Rapier R., Vaida F:, Hye R.J.:
Randomized Trial of Emergency Endoscopic Sclerotherapy Versus Emergency Portacaval Shunt for Acutely Bleeding Esophageal Varices in Cirrhosis. J Am Coll Surg 2009;209:25-40.
116. Almansa C, Krishna M, Buchner AM, Ghabril MS, Talley N, DeVault KR, Wolfsen H, Raimondo M, Guarderas JC, Achem SR.: Seasonal distribution in newly diagnosed cases of eosinophilic esophagitis in adults. Am J Gastroenterol. 2009 Apr;104(4):828-33.
117. Korsapati H, Babaei A, Bhargava V, Dohil R, Quin A, Mittal RK.: Dysfunction of the longitudinal muscles of the oesophagus in eosinophilic oesophagitis. Gut. 2009 Aug;58(8):1056-62.
118. Doo E-Y. et al: Oesophageal strictures caused by the ingestion of corrosive agents: effectiveness of balloon dilatation in children. Clinical Radiology 2009; 64:265-271.
119. Kim J.H. et al: Temporary metallic stent placement in the treatment of refractory benign esophageal strictures: results and factors associated with outcome in 55 patients. Eur Radiol 2009;19:384-390.
120. Dua KS, Vleggaar FP, Santharam R, Siersema PD.: Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study.. Am J Gastroenterol. 2008 Dec;103(12):2988-94.
121. Jeon SR, Eun SH, Shim CS, Ryu CB, Kim JO, Cho JY, Lee JS, Lee MS, Jin SY.: Effect of drug-eluting metal stents in benign esophageal stricture: an in vivo animal study.. Endoscopy. 2009 May;41(5):449-56.
A nyelõcsõ 69
122.* Zhao J-G. et al: Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-years single-center experience. Eur Radiol 2009;19:1973-1980.
123.* Campos M.G., Vittinghoff E., Rabl C., Takata M., Gadenstatter M., Lin F., Ciovica R.: Endoscopic and Surgical Treatments for Achalasia. Ann Surg 2009;249:45-47.
124. Rebecchi F., Giaccone C., Farinelle E., Campaci R., Morini M.: Randomized Controlled Trial of Laparoscopic Heller Myotomy Plus Dor Fundoplication Versus Nissen Fundoplication for Achalasia. Ann Surg 2008;248:1023-30.
125. Tsuboi K., Omura N., Yano F., Kashiwagi H., Yanaga K.: Results after laparoscopic Heller-Dor operation for esophageal achalasia in 100 consecutive patiens. Dis Esoph 2009;22:169-76.
126. Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ.: High-resolution manometry in clinical practice: utilizing pressure topography to classify oesophageal motility abnormalities. Neurogastroenterol Motil. 2009 Aug;21(8):796-806.
127. Bulsiewicz WJ, Kahrilas PJ, Kwiatek MA, Ghosh SK, Meek A, Pandolfino JE.: Esophageal pressure topography criteria indicative of incomplete bolus clearance: a study using high-resolution impedance manometry. Am J Gastroenterol. 2009 Nov;104(11):2721-8.
128. Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE.: Hyperdynamic upper esophageal sphincter pressure: a manometric observation in patients reporting globus sensation. Am J Gastroenterol. 2009 Feb;104 (2):289-98.
129. Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L, Vigneri S, Camerini G, Tutuian R, Savarino V.: Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut. 2009 Sep;58(9):1185-91.
130. Quispel R, van Boxel OS, Schipper ME, Sigurdsson V, Canninga-van Dijk MR, Kerckhoffs A, Smout AJ, Samsom M, Schwartz MP.: High prevalence of esophageal involvement in lichen planus: a study using magnification chromoendoscopy. Endoscopy. 2009 Mar;41(3):187-93.
131. Atug O, Dobrucali A, Orlando RC.: Critical pH level of lye (NaOH) for esophageal injury.. Dig Dis Sci. 2009 May;54(5):980-7.
132.* Schipper J.P., Pull ter Gunne A.F., Oostvogel H.J.M.: Spontaneous Rupture of the Oesophagus: Boerhaave’s Syndrome in 2008. Dig Surg 2009;26:1-6.
133. Wang Y., Zhang R., Zhou Y., Li X., Cheng Q., Wang Y., Liu K., Wang X.: Our experience on management of Boerhaave’s syndrome with late presentation. Dis Esoph 2009;22(1):62-67.
134. Sutcliffe R.P., Forshaw M.J., Datta G., Rohatgi A., Strauss D.C., Mason R.C., Botha A.J.: Surgical management of Boerhaave’s syndrome in a tertiary oesophagogastric centre. Ann R Coll Surg Engl 2009; 91(5):374-80.
135. Matsuki A., Kanda T., Kosugi S.I., Suzuki T., Hatekeyama K.: Gastric Tube Interposition for Corrosive Esophagitis Associated with Pyloric Stenosis. Surg Today 2009;39:261-64.
136. Szabó M., Pavlovics G., Papp A., Horváth Örs P.: Development of scar cancer after subtotal oesophagectomy for corrosive injury. Magy Seb 2009;62:71-74.
137. Fortelny R.H., Petter-Puchner A.H., Glaser K.S., Keibl C., Gruber-Blum S., Öhlinger W., Redl H.:
Fibrin Sealant (Tisseel) for Hiatal Mesh Fixation in an Experimental Model in Pigs. J Surg Res 2009, July (Epub).
138.* Asling B., Jirholt J., Hammond P., et al: Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia. Gut 2009;58: 1063-69.
139.* Vaninetti N., Williams L., Geldenhuys L., Porter G.A., Guernsey D.L., Casson A.G.: Regulation of CDX2 Expression in Esophageal Adenocarcinoma. Mol Carc 2009;48:965-74.
